Rare diseases
Investigational molecules
Locations
Back to Czechia24 clinical trials in Horovice, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer
CzechiaStudy of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
CzechiaA Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is
CzechiaStudy of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight
CzechiaA study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer
CzechiaA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
CzechiaStudy on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors
CzechiaStudy on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
CzechiaStudy of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
CzechiaCzechiaPetosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer
CzechiaEfficacy and Safety of Letrozole SIE Compared with Oral Letrozole, Both with Ribociclib, in Postmenopausal Women with HR‑Positive, HER2‑Negative Metastatic Breast Cancer
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Innovative trials focusing on hormone receptor-positive breast cancer treatments, including studies of novel therapies for both early-stage and advanced disease.
Multiple studies evaluating new therapeutic combinations to improve patient outcomes and reduce recurrence rates.
Research focusing on inflammatory bowel conditions and colorectal cancer, with emphasis on developing targeted treatments for various stages of disease.
Comprehensive evaluation of new therapeutic approaches for both inflammatory and oncological conditions.
Advanced research into non-small cell lung cancer treatments, particularly focusing on targeted therapies and immunotherapy combinations.
Investigating breakthrough treatments for specific genetic mutations in lung cancer.
Clinical trials examining new approaches for metastatic prostate cancer, including hormone-sensitive and castration-resistant cases.
Evaluating novel therapeutic combinations to improve survival rates and treatment outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
